Search results for "Anemia"

showing 10 items of 352 documents

Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice

2003

Abstract Purpose The effect of recombinant human erythropoietin (rhEPO) on the radiosensitivity of human tumor xenografts growing in anemic and nonanemic nude mice was studied. Methods and materials Anemia was induced by total body irradiation ([TBI], 2 × 4 Gy) of mice before tumor implantation into the subcutis of the hind leg. The development of anemia was prevented by rhEPO (750 U/kg s.c.) given 3 times weekly starting 2 weeks before TBI. Fourteen days after fractionated TBI (tumor volume of approx. 40 mm 3 ), single-dose irradiation of the tumor with varying doses was performed so that in full dose–response relationship for the probability of tumor cure was obtained. Results Radiation-i…

Cancer ResearchPathologymedicine.medical_specialtyAnemiamedicine.medical_treatmentTransplantation HeterologousDrug Evaluation PreclinicalUrologyMice NudeHindlimbRadiation ToleranceHemoglobinsMicemedicineAnimalsHumansRadiology Nuclear Medicine and imagingRadiosensitivityddc:610ErythropoietinRadiationbusiness.industryAnemiaSarcomaHypoxia (medical)Total body irradiationmedicine.diseaseCell HypoxiaRecombinant ProteinsRadiation therapyRadiation Injuries ExperimentalOncologyErythropoietinDose Fractionation RadiationHemoglobinmedicine.symptombusinessNeoplasm TransplantationWhole-Body Irradiationmedicine.drug
researchProduct

Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum

2008

Spontaneous apoptosis of bone marrow erythroid precursors accounts for the anemia that characterizes most low-grade myelodysplastic syndromes (MDS). We have shown that death of these precursors involved the Fas-dependent activation of caspase-8. To explore the pathway leading from caspase-8 activation to apoptosis, we transduced MDS bone marrow CD34(+) cells with a lentivirus encoding wild-type (WT) or endoplasmic reticulum (ER)-targeted Bcl-2 protein before inducing their erythroid differentiation. Both WT-Bcl-2 and ER-targeted Bcl-2 prevented spontaneous and Fas-dependent apoptosis in MDS erythroid precursors. ER-targeted Bcl-2 inhibited mitochondrial membrane depolarization and cytochrom…

Cancer ResearchProgrammed cell deathApoptosis[SDV.BC]Life Sciences [q-bio]/Cellular BiologyMitochondrionEndoplasmic Reticulum03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesmedicineHumansfas ReceptorErythropoietinComputingMilieux_MISCELLANEOUS030304 developmental biologyErythroid Precursor Cells0303 health sciencesbiologyCytochrome cEndoplasmic reticulumMembrane ProteinsAnemiaHematologyCaspase InhibitorsMitochondria3. Good healthCell biologyRed blood cellmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2OncologyErythropoietinApoptosisMyelodysplastic Syndromes030220 oncology & carcinogenesisCancer researchbiology.protein[SDV.IMM]Life Sciences [q-bio]/ImmunologyCalciumBone marrowmedicine.drug
researchProduct

The diagnostic plot: a concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy.

2005

Iron balance is regulated by the rate of erythropoiesis and the size of the iron stores. Anemia that accompanies infection, inflammation, and cancer (anemia of chronic disease) features normal or increased iron stores, although patients may have functional iron deficiency, namely, an imbalance between iron requirements of the erythroid marrow and the actual supply. The proportion of hypochromic red cells and the hemoglobin content of reticulocytes are direct indicators of functional iron deficiency. Biochemical markers, especially the soluble transferrin receptor/log ferritin ratio (ferritin index), are useful indicators of the iron supply to erythropoiesis. The relationship between functio…

Cancer Researchmedicine.medical_specialtyAnemiaIronInternal medicinemedicineHumansErythropoiesisErythropoietinSoluble transferrin receptorbiologyAnemia Iron-Deficiencybusiness.industryEpoetin alfaHematologyGeneral MedicineIron deficiencyIron Deficienciesmedicine.diseaseRecombinant ProteinsFerritinEpoetin AlfaEndocrinologyOncologyImmunologybiology.proteinErythropoiesisHemoglobinbusinessBiomarkersAnemia of chronic diseasemedicine.drugMedical oncology (Northwood, London, England)
researchProduct

53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PREL…

2015

Introduction. ACE-536, a recombinant fusion protein containing modified activin receptor type IIB and IgG Fc, is being developed for the treatment of anemias due to ineffective erythropoiesis, such as myelodysplastic syndromes (MDS). Patients with MDS often have elevated levels of erythropoietin (EPO) and may be non-responsive or refractory to erythropoiesis-stimulating agents (ESAs). MDS patients have also been shown to have increased serum GDF11 levels (Suragani R et al., Nature Medicine 2014) and increased Smad 2/3 signaling in the bone marrow (Zhou L et al., Blood 2008). ACE-536 binds to ligands in the TGF-s superfamily, including GDF11, inhibits Smad 2/3 signaling, and promotes late-st…

Cancer Researchmedicine.medical_specialtybusiness.industryAnemiaMyelodysplastic syndromesPhases of clinical researchDecitabineHematologymedicine.diseaseGastroenterologyGranulocyte colony-stimulating factorOncologyErythropoietinInternal medicinemedicineAbsolute neutrophil countbusinessIntensive care medicineLenalidomidemedicine.drugLeukemia Research
researchProduct

Anemia in Celiac Disease: Prevalence, Associated Clinical and Laboratory Features, and Persistence after Gluten-Free Diet

2022

Anemia is considered to be the most frequent extra-intestinal manifestation of Celiac Disease (CD). We assessed frequency, severity, morphologic features, and pathogenic factors of anemia in patients of the Sicilian Regional Network of Celiac Disease and attempted to identify putative pre-diet factors influencing anemia persistence. We retrospectively analyzed CD patients admitted to three centers between 2016–2020. 159 patients entered the study (129 females). More than half (54.7%) had mild-moderate, hypochromic and microcytic anemia, associated with below normal total serum iron and ferritin, indicative of iron deficiency anemia (IDA). One year after diagnosis, 134 patients were fo…

Celiac Disease; anemia; iron deficiency; gluten-free dietMedicine (miscellaneous)Celiac Disease anemia gluten-free diet iron deficiency
researchProduct

Predictive Power of the Tumor Oxygenation Status

1999

In most solid tumors the tissue pO2 status is poorer than in normal tissue at the site of tumor growth (for reviews see Vaupel et al., 1996, 1998; Vaupel and Hoeckel, 1998). Peculiarities of tumor tissue oxygenation can mainly be attributed to characteristic structural and functional abnormalities of the tumor microcirculation (perfusion-limited O2 delivery), to a deterioration of the diffusion-geometry (diffusion-limited O2 delivery), and—in some cases—to a reduced O2 carrying capacity of the blood due to tumor-associated anemia.

Cervical cancerPathologymedicine.medical_specialtyTumor hypoxiaAnemiabusiness.industrySoft tissue sarcomaOxygenationTumor Oxygenationmedicine.diseasemedicineTumor growthbusinessTissue po2
researchProduct

A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical impli…

2011

Abstract The treatment of iron deficiency anemia with polynuclear iron formulations is an established therapy in patients with chronic kidney disease but also in other disease areas like gastroenterology, cardiology, oncology, pre/post operatively and obstetrics’ and gynecology. Parenteral iron formulations represent colloidal systems in the lower nanometer size range which have traditionally been shown to consist of an iron core surrounded by a carbohydrate shell. In this publication, we for the first time describe the novel matrix structure of iron isomaltoside 1000 which differs from the traditional picture of an iron core surrounded by a carbohydrate. Despite some structural similaritie…

Chemical PhenomenaDrug CompoundingPharmaceutical ScienceIntravenous ironIron sucroseSodium ferric gluconateDisaccharidesFerric Compoundschemistry.chemical_compoundDrug Delivery SystemsIron Isomaltoside 1000medicineHumansParticle SizeInfusions IntravenousMolecular StructureHydrolysisRadiochemistryGeneral MedicineVitaminsCarbohydratemedicine.diseaseFerumoxytolMolecular WeightDextranBiochemistryIron-deficiency anemiachemistryBiotechnologymedicine.drug
researchProduct

Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by …

2013

Drug products containing iron oxide and hydroxide nanoparticles (INPs) are important for the treatment of iron deficiency anaemia. Pharmaceuticals prepared by the complexation of different kinds of INPs and carbohydrates have different physicochemical and biopharmaceutic characteristics. The increasing number of parenteral non-biological complex drugs (NBCD) containing iron requires physicochemical methods for characterization and enabling of cross comparisons. In this context the structure and the level of crystallinity of the iron phases may be connected to the in vitro and in vivo dissolution rates, which etiologically determine the therapeutic and toxic effects. X-ray powder diffraction…

Chemistry PharmaceuticalClinical BiochemistryInorganic chemistryIron oxideMetal NanoparticlesPharmaceutical ScienceContext (language use)engineering.materialCrystallography X-RayIron sucroseFerric CompoundsAnalytical Chemistrychemistry.chemical_compoundMicroscopy Electron TransmissionX-Ray DiffractionIron Isomaltoside 1000Drug DiscoveryHydroxidesmedicineInfusions ParenteralLepidocrociteSpectroscopyAnemia Iron-DeficiencyIron deficiencymedicine.diseaseFerumoxytolTreatment OutcomechemistryengineeringHydroxidePowder Diffractionmedicine.drugJournal of Pharmaceutical and Biomedical Analysis
researchProduct

Intraoperative transfusion practices and perioperative outcome in the European elderly: A secondary analysis of the observational ETPOS study

2022

PLOS ONE 17(1), e0262110 (2022). doi:10.1371/journal.pone.0262110

Clinical OncologyMaleScienceClinical Decision-MakingCancer TreatmentSurgical and Invasive Medical ProceduresGeographical LocationsDiagnostic MedicineOutcome Assessment Health CareMedicine and Health SciencesHumansBlood TransfusionProspective StudiesAgedAged 80 and overIntraoperative CareMultidisciplinaryTransfusion MedicineQRAnemiaHematologyClinical Laboratory SciencesHealth CareEuropeSurgical OncologyOncologyAge GroupsElective Surgical ProceduresPeople and PlacesMedicinePopulation GroupingsFemaleGeriatric CareClinical MedicineErythrocyte TransfusionResearch ArticlePLOS ONE
researchProduct

Evaluation of Clotting Factor Concentrates for Treatment of Thrombotic Thrombocytopenic Purpura.

2010

Abstract Abstract 3678 Introduction: Thrombotic thrombocytopenic purpura (TTP) is characterized by microthrombi, hemolytic anemia as well as thrombocytopenia. These symptoms are caused by a decreased activity of the protease ADAMTS13 which cleaves the von Willebrand Factor (VWF), due to mutation of the ADAMTS13-gene or autoantibodies. At the moment, the only available immediate therapy is plasmapheresis with Fresh Frozen Plasma (FFP) which may induce side effects. Therefore an alternative therapy might be the treatment with clotting factor concentrates. Methods: 40 plasma samples were tested, consisting of FFP and solvent/detergent treated plasma, four batches of each blood group; VWF/VIII …

Clotting factorHemolytic anemiamedicine.medical_specialtybiologyChemistrymedicine.medical_treatmentImmunologyAutoantibodyThrombotic thrombocytopenic purpuraCell BiologyHematologymedicine.diseaseBiochemistryADAMTS13EndocrinologyVon Willebrand factorhemic and lymphatic diseasesInternal medicineImmunologymedicinebiology.proteinPlasmapheresisFresh frozen plasmaBlood
researchProduct